Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Len W. Seymour"'
Autor:
William K. Taverner, Egon J. Jacobus, John Christianson, Brian Champion, Adrienne W. Paton, James C. Paton, Weiheng Su, Ryan Cawood, Len W. Seymour, Janet Lei-Rossmann
Publikováno v:
Molecular Therapy: Oncolytics, Vol 15, Iss , Pp 117-130 (2019)
Oncolytic viruses represent an emerging approach to cancer therapy. However, better understanding of their interaction with the host cancer cell and approaches to enhance their efficacy are needed. Here, we investigate the effect of chemically induce
Externí odkaz:
https://doaj.org/article/ed0fdf30ec0b400b8953b021722314be
Autor:
Eleanor M. Scott, Egon J. Jacobus, Brian Lyons, Sally Frost, Joshua D. Freedman, Arthur Dyer, Hena Khalique, William K. Taverner, Alison Carr, Brian R. Champion, Kerry D. Fisher, Len W. Seymour, Margaret R. Duffy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-18 (2019)
Abstract Background Tumour-associated macrophages (TAMs) are often implicated in cancer progression but can also exert anti-tumour activities. Selective eradication of cancer-promoting (M2-like) TAM subsets is a highly sought-after goal. Here, we hav
Externí odkaz:
https://doaj.org/article/d5fee97270fd469da9e2aa78cc47e661
Autor:
Janet Lei, Egon J. Jacobus, William K. Taverner, Kerry D. Fisher, Silvio Hemmi, Katy West, Lorna Slater, Fred Lilley, Alice Brown, Brian Champion, Margaret R. Duffy, Len W. Seymour
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-16 (2018)
Abstract Background Oncolytic viruses are currently experiencing accelerated development in several laboratories worldwide, with some forty-seven clinical trials currently recruiting. Many oncolytic viruses combine targeted cytotoxicity to cancer cel
Externí odkaz:
https://doaj.org/article/44a96f0e06e746ad9b16a6d3e39bf2b3
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Autor:
Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R. Duffy, Simon Alvis, Brian Champion, André Lieber, Terry Hermiston, Len W. Seymour, John Beadle, Kerry Fisher
Publikováno v:
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 62-74 (2017)
Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling i
Externí odkaz:
https://doaj.org/article/a7c13d435d3b499f8c2068ee8f9375b9
Autor:
Eleanor M, Scott, Sally, Frost, Hena, Khalique, Joshua D, Freedman, Len W, Seymour, Janet, Lei-Rossmann
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2058
The translational success of oncolytic virotherapies would benefit from the widespread use of clinically relevant ex vivo models. Malignant ascites, an accumulation of fluid in the peritoneum due to disseminated cancer, recapitulates many features of
Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus
Autor:
Sam Illingworth, Ying Di, Maxine Bauzon, Janet Lei, Margaret R. Duffy, Simon Alvis, Brian Champion, André Lieber, Terry Hermiston, Len W. Seymour, John Beadle, Kerry Fisher
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 62-74 (2017)
Molecular Therapy: Oncolytics, Vol 5, Iss C, Pp 62-74 (2017)
Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling i
Autor:
Len W. Seymour, Kerry D. Fisher
Publikováno v:
Human Gene Therapy; Sep2011, Vol. 22 Issue 9, p1041-1042, 2p
Autor:
Yousaf, Iris1 (AUTHOR) Iris.fnu@mayo.edu, Kaeppler, Jakob2 (AUTHOR) jakob.kaeppler@oncology.ox.ac.uk, Frost, Sally1 (AUTHOR) sally.frost@oncology.ox.ac.uk, Seymour, Len W.1 (AUTHOR) len.seymour@oncology.ox.ac.uk, Jacobus, Egon J.1 (AUTHOR) len.seymour@oncology.ox.ac.uk
Publikováno v:
Cancers. Apr2020, Vol. 12 Issue 4, p851-851. 1p.
Autor:
Pokrovska, Tzveta D.1 (AUTHOR) tzveta.pokrovska@oncology.ox.ac.uk, Jacobus, Egon J.1 (AUTHOR) egon.jacobus@oncology.ox.ac.uk, Puliyadi, Rathi2 (AUTHOR) rathi.puliyadi@oncology.ox.ac.uk, Prevo, Remko2 (AUTHOR) remko.prevo@oncology.ox.ac.uk, Frost, Sally1 (AUTHOR) sally.frost@oncology.ox.ac.uk, Dyer, Arthur1 (AUTHOR) arthur.dyer@oncology.ox.ac.uk, Baugh, Richard1 (AUTHOR) richard.baugh@oncology.ox.ac.uk, Rodriguez-Berriguete, Gonzalo2 (AUTHOR) gonzalo.rodriguez@oncology.ox.ac.uk, Fisher, Kerry1,3 (AUTHOR) brian.champion@psioxus.com, Granata, Giovanna2 (AUTHOR) giovanna.granata@oncology.ox.ac.uk, Herbert, Katharine2 (AUTHOR) Katharine.Herbert@glasgow.ac.uk, Taverner, William K.1 (AUTHOR) william.taverner@dtc.ox.ac.uk, Champion, Brian R.3 (AUTHOR), Higgins, Geoff S.2 (AUTHOR) geoffrey.higgins@oncology.ox.ac.uk, Seymour, Len W.1 (AUTHOR) len.seymour@oncology.ox.ac.uk, Lei-Rossmann, Janet1 (AUTHOR)
Publikováno v:
Cancers. Apr2020, Vol. 12 Issue 4, p798-798. 1p.
Publikováno v:
Human Gene Therapy; Nov2017, Vol. 28 Issue 11, p1033-1046, 14p